NewAmsterdam Pharma (NAMS) Enterprise Value (2022 - 2025)
Historic Enterprise Value for NewAmsterdam Pharma (NAMS) over the last 4 years, with Q3 2025 value amounting to -$702.9 million.
- NewAmsterdam Pharma's Enterprise Value fell 6628.76% to -$702.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$702.9 million, marking a year-over-year decrease of 6628.76%. This contributed to the annual value of -$834.2 million for FY2024, which is 14502.57% down from last year.
- According to the latest figures from Q3 2025, NewAmsterdam Pharma's Enterprise Value is -$702.9 million, which was down 6628.76% from -$739.2 million recorded in Q2 2025.
- NewAmsterdam Pharma's 5-year Enterprise Value high stood at -$340.4 million for Q4 2023, and its period low was -$834.2 million during Q4 2024.
- In the last 4 years, NewAmsterdam Pharma's Enterprise Value had a median value of -$462.5 million in 2022 and averaged -$541.2 million.
- Per our database at Business Quant, NewAmsterdam Pharma's Enterprise Value soared by 2390.49% in 2023 and then plummeted by 14502.57% in 2024.
- NewAmsterdam Pharma's Enterprise Value (Quarter) stood at -$447.4 million in 2022, then increased by 23.9% to -$340.4 million in 2023, then crashed by 145.03% to -$834.2 million in 2024, then increased by 15.73% to -$702.9 million in 2025.
- Its Enterprise Value stands at -$702.9 million for Q3 2025, versus -$739.2 million for Q2 2025 and -$808.5 million for Q1 2025.